Prosecution Insights
Last updated: October 01, 2026
Application No. 18/279,232

Small Molecule Degraders of CBP/p300 Proteins

Non-Final OA §112
Filed
Aug 29, 2023
Priority
Mar 04, 2021 — provisional 63/156,427 +2 more
Examiner
LEE, ANDREW P
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of Michigan
OA Round
1 (Non-Final)
48%
Grant Probability
Moderate
1-2
OA Rounds
2m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allowance Rate
287 granted / 594 resolved
-11.7% vs TC avg
Strong +23% interview lift
Without
With
+23.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
39 currently pending
Career history
645
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
57.0%
+17.0% vs TC avg
§102
7.7%
-32.3% vs TC avg
§112
21.2%
-18.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 594 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Claims 1, 3-6, 10-11, 14, 16, 19-20, 27, 29-30, 32-34, 36, and 39 are pending Claims 1, 3-6, 10-11, 14, 16, 19-20, 27, 29-30, 32-34, 36, and 39 are under consideration in the instant office action. Information Disclosure Statement The information disclosure statements (IDS) submitted on 03/05/2024, 05/03/2024, 05/27/2026 comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609. Accordingly, it has been placed in the application file and the information therein has been considered as to the merits. See attached copy of the PTO-1449. Priority This application claims benefit of U.S. Provisional Application No. 63/156,427 filed on 03/04/2021 and PCT Application No. PCT/US22/18597 filed on 03/03/2022. Election/Restrictions Applicant’s election without traverse of compound CP-047 in the reply filed on 05/27/2026 is acknowledged. Since compound CP-047 appears free of the prior art, the species election is withdrawn. Improper Markush Rejection Claims 1, 3-6, 10-11, 14, 16, 19-20, 27, 29-30, 32-34, 36, and 39 are rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117. The Markush grouping of compounds having the structure of Formula I is improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons: the species of the Markush group of compounds of instant Formula I do not share a “single structural similarity” because there are no required structural features within each variable definition such that each member of the group would have at least one structural feature, which feature is essential to the activity/function of the claimed compounds, in common. This rejection applies for the Markush groups used to define each of variables A and B1. Claim 1 encompasses a wide variety of chemical species which are in different recognized physical classes, and would embrace different chemical compounds that do not share any single structural similarity between the species. To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use. Positions A and B1 in instant Formula I encompassed by the claims is a variable (i.e., no single position in the chemical formula can be construed as being common among each member of the Markush group). To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use. Conclusion Claims 1, 3-6, 10-11, 14, 16, 19-20, 27, 29-30, 32-34, 36, and 39 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREW P LEE whose telephone number is (571)270-1016. The examiner can normally be reached Monday-Friday 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at (571)272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREW P LEE/Examiner, Art Unit 1691 /RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Aug 29, 2023
Application Filed
Sep 11, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746219
METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS
4y 7m to grant Granted Sep 29, 2026
Patent 12721857
BORATE COMPLEXES OF CHLOROGENIC ACID AND USES THEREOF
2y 4m to grant Granted Sep 01, 2026
Patent 12692231
TRYPTAMINE DERIVATIVES
1y 9m to grant Granted Jul 28, 2026
Patent 12685731
ORGANIC COMPOUNDS
5y 10m to grant Granted Jul 21, 2026
Patent 12655142
4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES
4y 4m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
48%
Grant Probability
71%
With Interview (+23.1%)
3y 3m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 594 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month